ArticleClinical rheumatology2026
Application of BCMA CAR-T in systemic lupus erythematosus.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSystemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by autoantibody production, complement activation, and a chronic relapsing-remitting course. Patients with refractory SLE often have limited treatment options.
methodsThree female patients with SLE (median age: 29 years) and active disease refractory to immunosuppressive therapies were enrolled in a B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell program. Autologous T cells were transduced with a lentiviral anti-BCMA CAR vector, expanded, and reinfused at a dose of 40 M CAR T cells on day 0 and day 2.
resultsBy day 13, clinical improvement and normalization of laboratory parameters were observed in all patients.
conclusionsThese findings suggest that BCMA CAR-T cell therapy is feasible, tolerable, and exhibits significant efficacy in the short term for the treatment of systemic lupus erythematosus (SLE), supporting further investigation into this therapy. Key Points • BCMA CAR-T cell therapy was used on three patients with treatment-resistant systemic lupus erythematosus (SLE). • The treatment led to rapid improvement in all patients and was found to be feasible, tolerable, and effective.
Indexed as
Identifiers
42010209What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.